GlassScriptPhysician profile
Renee Barrett
NPI 1568757979
$4,472.18
in general payments reported to CMS, 2019-2025
24 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,865 · 2022: $779 · 2023: $1,055 · 2024: $553 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,828.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,844.13 | 2021-2025 | Tysabri, Vumerity |
| Abbvie INC. | $623.09 | 2021-2025 | |
| Pfizer INC. | $506.83 | 2022-2025 | |
| Lilly USA, LLC | $310.88 | 2021-2025 | Emgality, Reyvow, Amyvid |
| Biohaven Pharmaceutical Holding Company LTD. | $229.26 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $116.55 | 2023 | Zeposia |
| Eisai INC. | $98.74 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $87.93 | 2022-2023 | Ultomiris |
| Acadia Pharmaceuticals INC | $78.10 | 2023-2024 | Nuplazid |
| Neurelis, INC. | $77.39 | 2022-2023 | Valtoco |
| Amgen INC. | $62.44 | 2023 | Aimovig |
| Lundbeck LLC | $60.55 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $58.80 | 2021-2023 | |
| Sk Life Science, INC. | $49.03 | 2023-2024 | |
| Collegium Pharmaceutical, INC. | $47.59 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $44.70 | 2022-2024 | Zeposia |
| Genzyme Corporation | $37.22 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $24.66 | 2021 | |
| Ucb, INC. | $24.60 | 2024 | Briviact |
| Tg Therapeutics, INC. | $21.18 | 2024 | |
| Janssen Pharmaceuticals, INC | $20.84 | 2022 | |
| Impel Pharmaceuticals INC. | $17.70 | 2023 | Trudhesa |
| Genentech USA, INC. | $17.02 | 2023 | Ocrevus |
| Allergan, INC. | $12.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.